Esophageal cancer secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{Esophageal cancer}} | {{Esophageal cancer}} | ||
{{CMG}} | {{CMG}};{{AE}} {{HM}} | ||
==Overview== | ==Overview== | ||
| Line 6: | Line 6: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
* | *Secondary prevention can be effective in high risk groups whom frequently smoke and drink alcohol if they are treated early enough in the dysplastic change before cancer occurs.<ref name="pmid3219974">{{cite journal |vauthors=Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP |title=[Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus] |language=Chinese |journal=Zhonghua Zhong Liu Za Zhi |volume=10 |issue=3 |pages=161–6 |year=1988 |pmid=3219974 |doi= |url=}}</ref> | ||
*A study was carried out in Hishun village, China. | |||
*Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high. | *Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high. | ||
* | *Subjects were examined by esophageal exfoliative cytology | ||
* | *One thrid of the participants had marked dysplasia | ||
* antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo. | |||
*The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo. | *The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo. | ||
*They | *They were placed on antitumor B for 3 years | ||
*The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%). | *The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%). | ||
*These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer. | |||
*These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer. | |||
==References== | ==References== | ||
Revision as of 14:35, 19 December 2017
|
Esophageal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Esophageal cancer secondary prevention On the Web |
|
American Roentgen Ray Society Images of Esophageal cancer secondary prevention |
|
Risk calculators and risk factors for Esophageal cancer secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]
Overview
Secondary prevention may be effective in reducing the incidence of esophageal cancer, if treated early at the dysplasia stage with monoclonal antibody therapy. At present, there is no particular program in place to reduce the incidence of esophageal cancer.
Secondary Prevention
- Secondary prevention can be effective in high risk groups whom frequently smoke and drink alcohol if they are treated early enough in the dysplastic change before cancer occurs.[1]
- A study was carried out in Hishun village, China.
- Due to different dietary factors, the incidence of esophageal cancer amongst these people was particularly high.
- Subjects were examined by esophageal exfoliative cytology
- One thrid of the participants had marked dysplasia
- antitumor B (Chinese herbs); retinamide (4-Ethoxycarbophenylretinamide) and placebo.
- The subjects with mild dysplasia were randomly divided into 2 groups for treatment with riboflavin and placebo.
- They were placed on antitumor B for 3 years
- The incidence of esophageal cancer in the antitumor B group was reduced by 53% as compared with that of the placebo group (8.3%).
- These results demonstrated that the secondary prevention of esophageal cancer is effective in the prevention of esophageal cancer.